S. Korean firm gets order for cloned dog

Here's a new business model for biotechnology: Pet cloning. South Korea's RNL Bio says it has its first $50,000 order to clone a dog from the biologic material remaining from a California woman's pet bull terrier. If more orders arrive, RNL says that it will hike its price to a post-launch $150,000. The company expects most of its cloned animals will be used in biomedical work and security. The company says they'll need to first make sure that the biologic material they're working with is viable for cloning purposes. If it is, they'll get started in April.

- check out the article from The Wall Street Journal

Related Articles:
S. Korean team to attempt first monkey clone. Report
Mature stem cells prove effective in cloning. Report
U.S. scientists renew stem cell cloning efforts. Report

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.